We observed that Mcl‐1 overexpression could inhibit Trametinib/TRAIL‐induced tumour cell death, while decreased Mcl‐1 increased Trametinib/TRAIL‐dependent apoptosis. The gene discussed is MCL1; the disease is neoplasm.